Category: Substances

280E, Act, analysis, analytics, business, Business Analysis, california, cannabis, cash, compliance, controlled, CSA, deduct, deduction, expense, Federal, finance, government, growing, industry, IRC, irs, law, legal, legalization, legalize, legislation, license, marijuana, market, MRB, Operations, payroll, product, recreational, regulation, regulations, regulatory, retail, revenue, schedule 1, state, substance, Substances, tax, taxation, taxes

How Section 280E is Still Hindering the Cannabis Industry

How Section 280E is Still Hindering the Cannabis Industry

The cannabis industry is an unprecedented industry and one under constant review and control. Following the November 2020 elections, fifteen states and […]

1, analysis, analytics, and Cosmetics Act, application, approval, approve, business, Business Analysis, cannabidiol, cannabis, cbd, clinical, clinical trials, compliance, consumer packaged goods, CPG, CSA, dea, derived, deschedule, descheduled, Dravet syndrome, drug, Drug Enforcement Administration, Epidiolex, epilepsy, extraction, FDA, FDCA, Federal, Federal Food, FFDCA, food and drug administration, formulation, government, GW, GW Pharma, hemp, industry, law, legal, legalization, legalize, legislation, Lennox-Gastaut syndrome, license, marijuana, market, medical, medicine, New, patent, pathway, patient, pharma, pharmaceutical, product, Product Development, program, regulation, regulations, regulatory, REMS, safety, schedule, seizures, state, Substances, thc, trial, TSC

How GW Pharma Won CBD

How GW Pharma Won CBD

As of this writing, the United States Food and Drug Administration (FDA) has approved GW Pharma’s CBD drug Epidiolex for treating profound […]